Low, High HDL Linked to Risk for Age-Related Macular Degeneration
By Elana Gotkine HealthDay Reporter
TUESDAY, May 27, 2025 -- Low and high high-density lipoprotein (HDL) are associated with an increased risk for age-related macular degeneration (AMD), according to a study published in the June issue of Ophthalmology.
Jimmy S. Chen, M.D., from the Shiley Eye Institute at the University of California San Diego in La Jolla, and colleagues conducted a cross-sectional retrospective data analysis involving 5,028 healthy participants and 2,328 patients with AMD from the All of Us research program to examine associations between clinical and genetic-based factors related to lipoprotein metabolism and the risk for AMD.
The researchers found that statin use and low and high HDL were significantly associated with an increased risk for AMD in a multivariable regression analysis. Certain HDL-associated single nucleotide polymorphisms (SNPs) increased the risk for AMD in multivariate regression. LPA, a major protein associated with lipoprotein(a), was identified as a novel SNP that is associated with an increased risk for AMD (odds ratio, 1.37).
"These findings highlight an exciting application of the wealth of clinical and genetic data in the All of Us dataset to highlight novel associations with the retinal disease pathophysiology of AMD," the authors write.
One author disclosed ties to Topcon, which manufactures equipment for ophthalmology and surveying.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
AAP Updates Screening Guidance for Child Mental Health, Behavioral Problems
MONDAY, Aug. 25, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Aug. 25 in Pediatrics, updated recommendations are presented for...
Discordance Seen Between Care Goals, Treatment Intent in Advanced Cancer
MONDAY, Aug. 25, 2025 -- More patients with advanced cancer report that their treatment discordantly focuses on longevity over comfort than patients with other illnesses...
Apitegromab Improves Motor Function in Spinal Muscular Atrophy
MONDAY, Aug. 25, 2025 -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.